Bicyclic Urea JAK2 Inhibitors for V617F Mutant Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current JAK2 small molecule inhibitors targeting the JAK2 kinase (JH1) domain fail to selectively target the JAK2 V617F mutant, which is associated with myeloproliferative neoplasms, while sparing essential JAK2 functions.

Innovation Solution

Development of bicyclic urea compounds that modulate the activity of JAK2, specifically targeting the JAK2 V617F mutant, thereby inhibiting its kinase activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current JAK2 small molecule inhibitors targeting the JAK2 kinase (JH1) domain are used, then JAK2 kinase activity is inhibited, but selective targeting of the JAK2 V617F mutant over the wild-type JAK2 is compromised

Engineering Contradiction:

Improveselectivity of JAK2 inhibitionVSAvoidloss of essential JAK2 functions

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing inhibitors that specifically target the mutant JAK2 V617F domain (JH2) with distinct structural features (N-substituted bicyclic urea moiety) different from wild-type JAK2 binders. This localized differentiation at the binding site enables selective inhibition of the mutant while preserving wild-type JAK2 function.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent introduces an intermediary approach by developing compounds that bind to the pseudokinase JH2 domain as a mediator between the mutant JAK2 and the inhibitory effect. This intermediary binding site (JH2 domain) serves as a selective target that distinguishes mutant from wild-type JAK2, allowing selective inhibition without affecting essential wild-type functions.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If JAK2 kinase (JH1) domain is targeted, then JAK2 activity is inhibited, but the ability to spare essential JAK2 functions is reduced

Engineering Contradiction:

Improveselectivity of mutant targetingVSAvoidpreservation of essential JAK2 functions

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies segmentation by dividing the JAK2 protein into functional domains (JH1 kinase domain and JH2 pseudokinase domain) and selectively targeting the JH2 domain in the mutant. This domain-specific targeting strategy allows inhibition of mutant JAK2 while preserving the essential functions of the JH1 domain in wild-type JAK2.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses the JH2 pseudokinase domain as an intermediary target that mediates selective inhibition. By binding to this intermediary domain rather than the catalytic JH1 domain, the inhibitors achieve mutant selectivity while allowing the JH1 domain to maintain essential functions in wild-type JAK2.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260049093A1Bicyclic Ureas As Kinase Inhibitors

Publication Date: 2026.02.19 INCYTE CORP

AI summary

The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.